|
1
|
Ji L, Mei X, Yuan W, Guo H, Zhang Y, Zhang Z, Zou Y, Liu Y, Zhu H, Qian Z, Shen Y. Plasma Interleukin-35 Levels Predict the Prognosis in Patients with HBV-Related Acute-on-Chronic Liver Failure. Viruses 2024; 16:1960. [PMID: 39772266 PMCID: PMC11680333 DOI: 10.3390/v16121960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2024] [Revised: 12/13/2024] [Accepted: 12/19/2024] [Indexed: 01/11/2025] Open
Abstract
This study aimed to investigate the impact of IL-35 on the prognosis of patients with HBV-ACLF. We recruited 69 patients with HBV-ACLF, 20 patients with chronic hepatitis B (CHB), 17 patients with liver cirrhosis (LC), and 20 healthy controls (HCs) from a regional infectious disease treatment center in China. Plasma levels of IL-35 at baseline were detected using ELISA. Plasma IL-35 levels in the HBV-ACLF group were the highest among all four groups. Furthermore, survivors exhibited significantly higher IL-35 levels than non-survivors (p < 0.001). IL-35 levels correlated with MELD (r = -0.678, p < 0.001), COSSH-ACLF IIs (r = -0.581, p < 0.001), alpha-fetoprotein (AFP) (r = 0.433, p < 0.001), creatinine (Cr) (r =-0.396, p = 0.001), and lactate (r =-0.38, p =0.001). The combination of plasma IL-35 and MELD score had the highest mortality prediction efficiency, with an area under the curve (AUC) of 0.895 (95% CI: 0.812-0.978, p < 0.001), a sensitivity of 80.6%, and a specificity of 93.9%. Additionally, the Kaplan-Meier analysis revealed that lower levels of IL-35 (≤191.5pg/mL) were associated with poorer survival rates in HBV-ACLF patients (p < 0.001). Our results demonstrated that IL-35 could be an effective predictive marker for the prognosis of HBV-ACLF and improve the predictive performance when combined with the MELD score.
Collapse
Affiliation(s)
- Liujuan Ji
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Xue Mei
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Wei Yuan
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Hongying Guo
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Yuyi Zhang
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Zhengguo Zhang
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Ying Zou
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Yu Liu
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Hui Zhu
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Zhiping Qian
- Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China; (L.J.); (X.M.); (W.Y.); (H.G.); (Y.Z.); (Z.Z.); (Y.Z.); (Y.L.); (H.Z.)
| | - Yinzhong Shen
- Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
| |
Collapse
|
|
2
|
Sun J, Zhang K, Yin Y, Qi Y, Li S, Sun H, Luo M, Sun Y, Yu Z, Yang J, Wu J, Chen L, Xu W, Dong L. Arecoline-Induced Hepatotoxicity in Rats: Screening of Abnormal Metabolic Markers and Potential Mechanisms. TOXICS 2023; 11:984. [PMID: 38133385 PMCID: PMC10748282 DOI: 10.3390/toxics11120984] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 11/28/2023] [Accepted: 11/30/2023] [Indexed: 12/23/2023]
Abstract
Arecoline is a pyridine alkaloid derived from areca nut in the Arecaceae family. It has extensive medicinal activity, such as analgesic, anti-inflammatory, and anti-allergic. However, the toxicity of Arecoline limits its application. Most current studies on its toxicity mainly focus on immunotoxicity, carcinogenesis, and cancer promotion. However, there are few systematic studies on its hepatotoxicity and mechanisms. Therefore, this research explored the mechanism of hepatotoxicity induced by Arecoline in rats and analyzed endogenous metabolite changes in rat plasma by combining network toxicology with metabolomics. The differential metabolites after Arecoline exposure, such as D-Lysine, N4-Acetylaminobutanal, and L-Arginine, were obtained by metabolomics study, and these differential metabolites were involved in the regulation of lipid metabolism, amino acid metabolism, and vitamin metabolism. Based on the strategy of network toxicology, Arecoline can affect the HIF-1 signaling pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, and other concerning pathways by regulating critical targets, such as ALB, CASP3, EGFR, and MMP9. Integration of metabolomics and network toxicology results were further analyzed, and it was concluded that Arecoline may induce hepatotoxicity by mediating oxidative stress, inflammatory response, energy and lipid metabolism, and cell apoptosis.
Collapse
Affiliation(s)
- Jing Sun
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China; (M.L.); (J.Y.); (J.W.)
| | - Kai Zhang
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Yihui Yin
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Yunpeng Qi
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Siyuan Li
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Haonan Sun
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Min Luo
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China; (M.L.); (J.Y.); (J.W.)
| | - Yixuan Sun
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Zhiying Yu
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Jie Yang
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China; (M.L.); (J.Y.); (J.W.)
| | - Jingjing Wu
- School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China; (M.L.); (J.Y.); (J.W.)
| | - Lijuan Chen
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Wenjuan Xu
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| | - Ling Dong
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China; (J.S.); (K.Z.); (Y.Y.); (Y.Q.); (S.L.); (H.S.); (Y.S.); (Z.Y.); (L.C.)
| |
Collapse
|